Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

Inclusion Criteria:

• Subjects willing and able to provide voluntary informed consent and to follow protocolrequirements.
• Male or females aged ≥18 years.
• Subjects having body mass index (BMI) ≥18.50 kg/m2.
• Subjects with chronic open-angle glaucoma or ocular hypertension in both eyes.
• Subjects requiring treatment of both eyes and able to discontinue the use of allocular hypotensive medication(s) or switch ocular hypotensive medications and undergoappropriate washout period.
• Adequate washout period prior to baseline of any ocular hypotensive medications as perthe table below (to minimize potential risk to subjects due to intraocular pressure (IOP) elevations during the washout period, the Investigator may choose to substitutea parasympathomimetic or carbonic anhydrase inhibitor in place of a sympathomimetic,alpha-agonist, beta-adrenergic blocking agent, or prostaglandin; however, all thesubjects must have discontinued their ocular hypotensive medications for the minimumwashout period.
• Baseline (Day 0/hour 0) IOP ≥22 mm Hg and <35 mm Hg in each eye,
• Subjects' IOP is likely to be controlled with monotherapy as per the Investigator'sdiscretion.
• Baseline best corrected visual acuity equivalent to Snellen acuity of 20/100 or betterin each eye, using a logarithmic visual acuity chart for testing at 10 feet (3meters).
• Women of childbearing potential (defined as women physiologically capable of becomingpregnant unless they are using an effective method of contraception during the dosingof the study drug) practicing any of the following acceptable methods ofcontraception:

1. Oral or parenteral (injection, patch, or implant) hormonal contraception whichhas been continuously used for at least 1 month prior to first dose of studymedication
2. Intrauterine device (IUD) or intrauterine system (IUS)
3. Double barrier method of contraception (condom and occlusive cap or condom andspermicidal agent)
4. Male sterilization (at least 6 months prior to screening, should be the sole malepartner for that subject)
5. Female sterilization (surgical bilateral oophorectomy) or tubal ligation at least 6 weeks prior to study participation
6. Total abstinence; partial abstinence is not acceptable

• No history of addiction to any recreational drug or drug dependence or alcoholaddiction.

Exclusion Criteria:

• Female who are pregnant, lactating or planning a pregnancy.
• Contraindication or known hypersensitivity to Bimatoprost, related class of drugs, orany of the excipients of formulation.
• Current or past history of severe hepatic or renal impairment.
• Current or history within 2 months prior to baseline of any other significant oculardisease, e.g., corneal edema, uveitis, ocular infection, or ocular trauma in eithereye (Note: stable myopia, strabismus, and cataracts as per the Investigator'sdiscretion will be allowed provided that the other inclusion/exclusion criteria aremet).
• Current corneal abnormalities that would prevent accurate IOP readings with Goldmannapplanation tonometer.
• Functionally significant visual field loss in the Investigators' opinion.
• Subject with corneal grafts.
• Subject has contraindication to pupil dilation
• Use at any time prior to baseline of an intraocular corticosteroid implant
• Use of contact lens within 1 week prior to baseline
• Use within 2 weeks prior to baseline of 1) a topical ophthalmic corticosteroid or 2) atopical corticosteroid
• Use within 1 month prior to baseline of 1) a systemic corticosteroid or 2) high dosesalicylate therapy defined as 325 mg/day and taken on 3 consecutive days.
• Use within 6 months prior to baseline of intravitreal or subtenon injection of anophthalmic corticosteroid
• Underwent within 6 months prior to baseline any other intraocular surgery (e.g.,cataract surgery).
• Underwent within 12 months prior to baseline any refractive surgery, filteringsurgery, or laser surgery for IOP reduction (e.g., laser trabeculoplasty).
• Amblyopia - only one sighted eye.
• Subjects with a history of IOP previously uncontrolled on bimatoprost monotherapy
• Significant ocular surface findings (e.g., hyperemia or irritation, mild or greater)in either eye found on gross macroscopic or slit lamp examination
• Severe retinal disease or other severe ocular pathology, such as glaucomatous damagewith a cup/disk ratio greater than 0.8 (not including physiological cupping in theInvestigators' opinion) or split fixation
• Chronic use of any systemic medication that may affect IOP with less than 3 monthsstable dosing regimen (i.e., sympathomimetic agents, beta-adrenergic blocking agents,alpha-agonists, alpha-adrenergic blocking agents, calcium channel blockers,angiotensin-converting enzyme inhibitors, etc.)
• Central Corneal thickness (CCT) <450 microns or >650 microns
• Known history or presence of any uncontrolled systemic disease (e.g., cardiovasculardisease, hypertension, diabetes mellitus, hepatic impairment, etc.)
• History of recurrent ocular seasonal allergies within the past 2 years
• Any other medical condition or serious intercurrent illness that, in theInvestigator's opinion, may make it undesirable for the subject to participate in thestudy and would limit adherence to the study requirements
• Participation in any clinical study within 90 days before the first dose of the studydrug
• Subjects with documented history of positive serology for Hepatitis B Virus (HBV),Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV) infection
• Subjects with positive urine pregnancy test
• Subjects with confirmed novel coronavirus infection (COVID-19).